首页 | 本学科首页   官方微博 | 高级检索  
     


Preferential binding of adriamycin and nogalamycin to DNase-I hypersensitive sites of Sarcoma-180 chromatin
Authors:C K Panda  K Choudhury  R K Neogy
Affiliation:1. Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA;2. BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA;3. BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA;4. Division of Rheumatology, Zucker School of Medicine at Hofstra–Northwell, Great Neck, NY, USA;5. Centre for Inflammatory Disease, Monash University, Melbourne, VIC, Australia;6. Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, CA, USA;7. BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden;1. Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;2. The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;3. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;4. Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;1. Academy of Immunology and Microbiology, Institute for Basic Science, Pohang, Gyeongbuk 37673, Republic of Korea;2. Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang, Gyeongbuk 37673, Republic of Korea;3. Department of Rheumatology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon, Gyeonggi-do 16499, Republic of Korea
Abstract:Binding of nogalamycin and adriamycin with Sarcoma-180 ascites tumor cell chromatin was studied by a spectrofluorometric method. There was significant reduction in the number of available drug binding sites per nucleotide when the chromatin was digested with DNase I for a period which releases only 7% of the chromosomal DNA. Results indicate preferential binding of these drugs with DNase I hypersensitive sites of chromatin. The DNase-I hypersensitive sites of chromatin were shown to correlate to the sequences required for gene expression. Further digestion with DNase I increases availability of drug binding sites, probably due to relaxation of the compact chromatin.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号